Last week, prominent tech site Gigaom ceased operations with the terse note “Gigaom recently became unable to pay its creditors in full at this time”.

Started in 2006 by Om Malik, the site had raised about $40 million over that period to create a technology news site, an IT analysis business and another business running IT events. None of them could make enough money to cover the $400,000 a month needed to keep the business going.

I’ve probably lost count of the number of ‘WATER ON MARS’ and related headlines I’ve read over the years. It’s an interesting case study of how a scientific theory gains support as more evidence is collected, until it becomes something ‘that is known’.

But last week we heard evidence that Mars has lost some water – an entire oceans worth in fact.

Pi Day – on March 14th – will be particularly memorable this year: the date can be written 3/14 by those who opt for the month then day format, which is Pi to two decimal places, 3.14.

If you include the year this year then that gives 3/14/15, which is Pi to four decimal places, 3.1415.

This happens only once a century, and the Museum of Mathematics in New York City, among others, is taking Pi Day 2015 one step further, by celebrating at 9:26 pm, adding three more digits to Pi, 3.1415926.

Speech problems in early childhood are common.

Why do people cooperate? This isn’t a question anyone seriously asks. The answer is obvious: we cooperate because doing so is usually synergistic. It creates more benefit for less cost and makes our lives easier and better.

Maybe it’s better to ask why don’t people always cooperate. But the answer here seems obvious too. We don’t do so if we think we can get away with it. If we can save ourselves the effort of working with someone else but still gain the benefits of others’ cooperation. And, perhaps, we withhold cooperation as punishment for others’ past refusal to collaborate with us.

This year marks the 50th anniversary of cisplatin’s accidental discovery as an anti-cancer drug. Despite its horrible side effects, and the ability of cancers to become resistant to it, the drug remains as relevant now as it was when it first reached the market.

And the good news is that the drug can, and is, being made better. New formulations are being designed to make it more effective and less toxic.